Stock Price
1,490.00
Daily Change
0 0%
Yearly
-29.05%
Q1 Forecast
1,482.10
Rating
Sell
Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Width
Height

Peers Price Day Year Date
ASII Astra International 5,225.00 0 0% -15.04% Mar/01
CPIN Charoen Pokphand 4,920.00 80.00 1.65% -9.31% Mar/01
F34 Wilmar International 3.33 0.01 0.30% -15.48% Mar/01
GGRM Gudang Garam Tbk 20,225.00 -100.00 -0.49% -19.66% Mar/01
HMSP Hanjaya 865.00 0 0% -26.69% Mar/01
ICBP Indofood Cbp 11,625.00 75.00 0.65% 18.02% Mar/01
IHH Ihh Healthcare 6.14 -0.01 -0.16% 4.24% Mar/01
INDF Indofood Sukses 6,675.00 50.00 0.75% 6.80% Mar/01
INTP Indocement Tung 9,175.00 100.00 1.10% -17.53% Mar/01
MYOR Mayora Indah 2,490.00 30.00 1.22% -9.12% Mar/01
PGAS Perusahaan Gas 1,100.00 10.00 0.92% -31.25% Mar/01
RICHT Richter Gedeon 9,625.00 -45.00 -0.47% 26.31% Mar/01
SMGR Semen Indonesia 6,050.00 -50.00 -0.82% -15.38% Mar/01
THBEV Thai Beverage PCL 0.51 0 0% -21.09% Mar/01
UNTR United Tractors 23,625.00 100.00 0.43% -16.59% Mar/01
UNVR Unilever Ind 2,690.00 -40.00 -1.47% -35.18% Mar/01

Indexes Price Day Year Date
JCI JCI 7312 -4.20 -0.06% 6.63% Mar/01

Kalbe Farma traded at 1,490.00 this Friday March 1st, decreasing 0 or 0 percent since the previous trading session. Looking back, over the last four weeks, Kalbe Farma lost 3.25 percent. Over the last 12 months, its price fell by 29.05 percent. Looking ahead, we forecast Kalbe Farma to be priced at 1,482.10 by the end of this quarter and at 1,458.66 in one year, according to Trading Economics global macro models projections and analysts expectations.